ATR-258
Asset
Selectively activates GRK-biased β2-adrenergic receptor signaling in skeletal muscle.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Lipid and ceramide metabolism
- 2
- Indications
- 1
- Trial
- 1
- Developer
Indications
2Overweight and obesity
Phase 2, Active not recruiting, NCT07421024, clinicaltrials.gov, 17 Oct 2026
Obesity
Phase 1, longevity.technology, 5 Oct 2026
In the full profile
- Targets and what it contains3
- Owner and partners1
- Trials1
- Evidence for its targets3
- Competitors12
- Aging relevance1
- Signals3
Every asset’s record: target, stage, trials and the evidence behind it.